SUNNYVALE, Calif.
and BOSTON, Oct. 28, 2012
/PRNewswire/ -- ASTRO 2012 -- Accuray Incorporated (Nasdaq:
ARAY), the premier radiation oncology company, today launched its
new TomoTherapy® H™ Series, featuring the TomoHDA™ System, with
faster planning, faster delivery and increased quality. The TomoHDA
System was unveiled at the 54th Annual American Society for
Radiation Oncology (ASTRO) Meeting in Boston. Key features of the TomoHDA System
include:
- Accuray's new TomoEDGE™ dynamic jaws technology provides users
with added flexibility in treatment delivery by sharpening dose
fall off and accuracy. In many cases the use of TomoEDGE for head
and neck tumors and prostate cancer treatments has resulted in the
reduction of beam-on time by half. With the TomoHDA™ System this
new technology is standard and can be applied to both TomoHelical™
and TomoDirect™ treatment modes for 3DCRT and IMRT deliveries.
- The high-performance VoLO™ Technology – an enhancement to the
TomoTherapy® treatment planning system – leverages the new dose
calculation algorithm and advanced graphics processing technology
to increase clinical efficiency, throughput and flexibility in
developing both simple and the most complex radiation therapy
plans.
"We are committed to our TomoTherapy customers and continue to
innovate to provide the most advanced treatments in radiation
oncology with the goal of improving patient care," said
Joshua H. Levine, president and
chief executive officer of Accuray. "The new TomoTherapy H™ Series
offers treatment solutions for the entire spectrum of radiation
therapy. It will enable unprecedented speed and efficiency ensuring
the highest quality of care from the routine to the most complex
cases."
The TomoHDA System is a fully-integrated 3D image-guided, full
spectrum radiation therapy system and builds upon the proven
TomoTherapy Hi-Art® and TomoHD™ technologies. The TomoHDA System
offers multiple new benefits including performance enhancements,
unrivaled dose distributions and faster treatments.
The TomoHDA System is part of the new TomoTherapy H Series.
Included in this series of products, is the new TomoH™ System, the
gold standard for image-guided IMRT (intensity-modulated radiation
therapy) treatment, providing streamlined 3D CT daily image
guidance and ultrafast MLC (multileaf collimator) modulation,
enabling the delivery of the dose to achieve excellent target
homogeneity while sparing surrounding healthy tissue. Also included
in the series is the TomoHD™ System - including TomoDirect - a full
spectrum solution that provides high quality treatments to every
patient for any clinical indication requiring radiotherapy.
The new TomoEDGE™ dynamic jaws are capable of sharpening the
dose and allow customers to treat more patients with the
TomoTherapy System. The jaws are optimized to sweep across the
target, minimizing dose to healthy tissue and critical structures
adjacent to the target and opening to the desired maximum size to
reduce treatment time. The result is a balanced treatment delivery
that is as unique as each patient.
Using the high-performance VoLO Technology, the TomoHDA™ system
allows ultra fast creation of highly conformal treatment plans with
the flexibility to design a personalized treatment plan specific to
the individual needs of each patient. For example, the application
of VoLO technology on breast cancer treatment plans has been shown
to reduce dose calculation and treatment planning optimization time
to as few as three minutes. TomoHDA also includes a fan-beam
computed tomography (CT) system capable of producing images 50
percent faster, facilitating improved patient re-positioning time
and therefore less overall time for the patient to be on the
treatment couch.
"Having been involved in the creation of and research
collaboration for the new TomoEDGE, we have seen firsthand that
this is one of the most versatile radiation therapy treatment
options available," said PD Dr. Florian
Sterzing, M.D., Consultant Radiation Oncologist at
University Clinic of Heidelberg. "The new functionality enables
improved quality of radiotherapy application and allows us to treat
even more cancer patients."
The TomoHDA System also includes Citrix®-based remote planning
with web-based review capabilities, providing the ultimate
flexibility for clinicians to develop and approve treatment plans
from virtual workstations.
"TomoTherapy's ability to treat the full range of disease sites,
including even the most complex tumors, makes it an invaluable
resource for cancer patients," said Wade
Gebara, M.D. Chief of Radiation Oncology at Berkshire
Medical Center, Pittsfield, Mass.
"With increased speed and reliability, the new TomoTherapy System
will provide the opportunity for more patients to benefit from this
personalized technology."
Also on display in Accuray's ASTRO booth (#7101) is the
CyberKnife M6 FIM Sytem – part of the CyberKnife®
M6™ Series – which is pending FDA 510(k) clearance and
not yet available for commercial distribution in the United States. The new CyberKnife M6 FIM
and FM Systems feature the InCise™ Multileaf Collimator, which
combines the benefits of beam shaping with the flexibility of
non-isocentric, non-coplanar delivery. The new InCise Multileaf
Collimator (MLC) was designed specifically for stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
treatments, giving the system the capability to extend its
radiosurgical precision into a broader field of applications. The
system is intended to treat large and irregular tumors more
efficiently with excellent dose gradients, to expand the number of
patients eligible for treatment.
Researchers at Fox Chase Cancer Center in Philadelphia – who compared treatment plans
created with a theoretical MLC on the CyberKnife System to those
created originally with the CyberKnife Iris™ Collimator and
conventional Intensity-Modulated Radiation Therapy (IMRT) plans –
found that an MLC mounted on a robotic arm could potentially offer
numerous clinical benefits, including faster treatment delivery,
better target coverage and a sharper dose fall off could be
achieved than a typical gantry- based IMRT plan or previous
CyberKnife treatments. The Fox
Chase researchers demonstrated the potential to create
treatment plans that would spare critical structures around tumors
better with a robotically mounted MLC, providing the ability to
treat tumors using a higher dose without increasing the normal
tissue toxicity.
Dates, times and locations of ASTRO clinical presentations
featuring the CyberKnife and TomoTherapy Systems are available
here.
About Accuray
Accuray Incorporated (Nasdaq: ARAY),
based in Sunnyvale, Calif., is the
premier radiation oncology company that develops, manufactures and
sells personalized innovative treatment solutions that set the
standard of care, with the aim of helping patients live longer,
better lives. The Company's leading edge technologies – the
CyberKnife and TomoTherapy Systems – are designed to deliver
radiosurgery, stereotactic body radiation therapy, intensity
modulated radiation therapy, image guided radiation therapy, and
adaptive radiation therapy. To date 642 systems have been installed
in leading hospitals around the world. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expansion of the Company's
global presence, quality of treatments, accuracy, dose delivery,
clinical efficiency, continual innovation, pending regulatory
clearance, treatment times, dose sculpting, and the Company's
leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including risks detailed from time to time under the
heading "Risk Factors" in the company's report on Form 10-K filed
on September 10, 2012. Forward-looking statements speak only as of
the date the statements are made and are based on information
available to the Company at the time those statements are made
and/or management's good faith belief as of that time with respect
to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly,
investors should not place undue reliance on any forward-looking
statements.
SOURCE Accuray Incorporated